Lifestyle

FDA Turns Down Lung Cancer Therapy Ivonescimab Over Survival Data

Regulators decided that slowing tumor growth without extending overall survival failed to show an acceptable balance of clinical benefits.

thenews.com.pk

Federal regulators declined to clear Summit Therapeutics' marketing application for ivonescimab alongside chemotherapy for advanced EGFR-mutated non-small cell lung cancer, Summit disclosed on November 15, 2026. The agency determined that the drug did not show clear proof of effectiveness because it did not help patients live significantly longer.

The agency concluded that delaying cancer growth without extending patients' lives failed to provide a favourable balance of benefits against risks. In the global Phase 3 HARMONi trial, the drug regimen succeeded at delaying tumour progression compared with chemotherapy alone, but did not achieve statistical significance in prolonging life. During that study, 7.3 percent of participants receiving ivonescimab stopped taking it due to adverse effects versus 5.0 percent on placebo, while treatment-related deaths were 1.8 percent and 2.3 percent respectively.

Unmet Need After Targeted Therapy

Federal regulators have not approved any treatment that has shown a proven survival advantage for patients in this post-targeted therapy lung cancer category. Currently, no bispecific antibody targeting both PD-1 and VEGF holds clearance in the United States.

"We are disappointed for patients and their families awaiting additional treatment options in this setting," said Robert W. Duggan, chairman and co-chief executive officer of Summit Therapeutics. Summit has not announced when it might seek approval again or what additional clinical steps it will take.

Share This Article
Aybeniz is Miraz TV’s Baku representative and a creative team member. She stands out for her professional approach, strong communication skills, and creative perspective. Her dynamic and responsible work makes her a valued member of the Miraz TV team.